VYNE Therapeutics (NASDAQ:VYNE) Research Coverage Started at BTIG Research

BTIG Research began coverage on shares of VYNE Therapeutics (NASDAQ:VYNE) in a research note issued to investors on Monday, Marketbeat reports. The firm issued a buy rating and a $8.00 price objective on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $5.75 price target on shares of VYNE Therapeutics in a report on Friday, November 8th.

VYNE Therapeutics Price Performance

VYNE Therapeutics stock opened at $2.82 on Monday. The firm has a market capitalization of $41.60 million, a P/E ratio of -3.28 and a beta of 1.32. The stock has a fifty day moving average price of $2.33 and a two-hundred day moving average price of $2.19. VYNE Therapeutics has a 52-week low of $1.57 and a 52-week high of $4.24.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in VYNE Therapeutics stock. Lynx1 Capital Management LP bought a new position in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics comprises 0.0% of Lynx1 Capital Management LP’s holdings, making the stock its 17th largest holding. Lynx1 Capital Management LP owned approximately 0.11% of VYNE Therapeutics as of its most recent filing with the Securities & Exchange Commission. 83.78% of the stock is currently owned by institutional investors.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.